Benzinga | Jun 1, 2021 07:08AM EDT

Precision BioSciences Announces Publication Of Study In Nature Communications Using Engineered ARCUS Nuclease To Target Mutant Mitochondrial DNA In Vivo

Learnings to be Presented by Carlos Moraes, Ph.D., from University of Miami at UMDF's Mitochondrial Medicine Symposium on June 4, 2021

Precision BioSciences, Inc. (NASDAQ:DTIL), a clinical stage biotechnology company developing allogeneic CAR T and in vivo gene correction therapies with its ARCUS(r) genome editing platform, today announced a new paper published online in Nature Communications that reportspreclinical results using an ARCUS nuclease to target mitochondrial DNA (mtDNA) and reduce levels of mutant mtDNA in vivo.

The study, "Mitochondrial targeted meganuclease as a platform to eliminate mutant mtDNA in vivo" was led by Carlos T. Moraes, Ph.D., Esther Lichtenstein Professor in Neurology at the University of Miami Miller School of Medicine, with Ugne Zekonyte as first author.